CNS Pharmaceuticals, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- CNS Pharmaceuticals, Inc. (Nasdaq: CNSP) is a clinical-stage biopharmaceutical company that develops novel anti-cancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors, with a primary focus on glioblastoma multiforme (GBM) and other high-grade gliomas. The company advances a pipeline featuring its lead candidate TPI 287, a late-stage blood-brain barrier permeable abeotaxane taxane-derivative studied in over 350 patients for recurrent GBM as monotherapy and in combination with bevacizumab, as well as indications including pediatric high-grade gliomas, brain metastases with radiation therapy, and primary CNS lymphoma; it previously developed Berubicin, an anthracycline that crosses the blood-brain barrier for GBM and other CNS malignancies. Founded in 2017 and headquartered in Houston, Texas, CNS Pharmaceuticals targets oncology patients globally through clinical trials and maintains license agreements, such as with Cortice Biosciences for certain assets. In recent developments, the company in-licensed TPI 287 to expand its pipeline targeting recurrent GBM and plans FDA consultations for a potential registration study; it reported third quarter 2025 financial results, announced abstract acceptances for the Society for Neuro-Oncology 30th Annual Meeting, and presented at the H.C. Wainwright 27th Annual Global Investment Conference.
CNS Pharmaceuticals CEO, Rami Levin, Participates in Virtual Investor CEO Connect Segment Highlighting Company's Recent Strategic Transformation Progress
Forget the 242% Biotech Meme. This Brain Cancer Stock Has a $38 Analyst Target and Trades at $6
CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress
What's Going On With CNS Pharmaceuticals Stock On Wednesday?
Nano-Cap CNS Pharmaceuticals Stock Explodes As Capital Raise Fuels Pivot
CNS Pharmaceuticals Announces Oversubscribed $22.5 Million Private Placement Financing
CNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology Pipeline
CNS Pharmaceuticals Appoints Lynne Kelley, MD, FACS, as Chief Medical Officer, Completing Executive Leadership Team
CNS Pharmaceuticals Appoints Multiple Key Executives to Drive Company's Recently Initiated Strategic Transformation
CNS Pharmaceuticals (NASDAQ:CNSP) Shares Down 11.2% – Here’s What Happened
CNS Pharmaceuticals Issues Letter to Shareholders
CNS Pharmaceuticals Announces CEO Transition
CNS Pharmaceuticals, Inc. (CNSP) Shareholder/Analyst Call Prepared Remarks Transcript
CNS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update
CNS Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentation at the Society of NueroOncology (SNO) 30th Annual Meeting
CNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference
CNS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Update
CNS Pharmaceuticals to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
CNS Pharmaceuticals to Participate in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference
CNS Pharmaceuticals Announces Reverse Stock Split